Description de l'entreprise
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies.
Conseil d'administration & Conseil de surveillance
| PDG |
| Peter Janssen |
| Conseil d'administration |
| Ainhoa Mendizabal Zubiaga, Dr. Jörg Schüttrumpf, Dr. Michael Ramroth, Dr. Georg Floß |
| Conseil de surveillance |
| Dr. Bernhard Ehmer, David Bell, Uta Kemmerich-Keil, Jürgen Heilmann, Dirk Schuck, Raimon Grifols Roura |
Données de l'entreprise
| Nom: |
Biotest AG |
| Adresse: |
Landsteinerstraße 5,D-63303 Dreieich |
| Téléphone: |
+49-6103-801-0 |
| Fax: |
+49-6103-801-150 |
| Courriel: |
mail@biotest.de
|
| Internet: |
www.biotest.de |
| Industrie: |
Healthcare |
| Secteur: |
Medical Products |
| Sous-secteur: |
Advanced Medical Devices |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
14/10/1987 |
Relations avec les investisseurs
| Nom: |
Dr. Monika Buttkereit |
| Téléphone IR: |
+49-6103-801-4406 |
| IR-Fax: |
+49-6103-801-347 |
| E-mail IR: |
investor_relations@biotest.de
|
